Form 4: Aquestive Therapeutics CEO Reports Stock Transaction
Insider Transaction (Form 4)
Daniel Barber, President and CEO and a Director of Aquestive Therapeutics, Inc., reported multiple transactions in common stock on September 8, 2026.
Summary
- In-the-money derivative exercise: acquired 91,743 Common Stock at $0.96 ($88,073) on September 8, 2026; holds 677,317 after (Direct).
- In-the-money derivative exercise: disposed of 91,743 Warrant (Right to Buy) on September 8, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Daniel Barber — Director, Officer (President and CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-08 | In-the-money derivative exercise | Common Stock | 91,743 | $1 | $88.1K | 677,317 |
| 2026-09-08 | In-the-money derivative exercise | Warrant (Right to Buy) | 91,743 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-08 | In-the-money derivative exercise (91,743 shares) |
| 2026-09-08 | In-the-money derivative exercise (91,743 shares) |
Keywords
insider transaction, Form 4, AQST, Aquestive Therapeutics, Inc., neutral, Daniel Barber
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.